Overview

A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
0
Participant gender:
Male
Summary
To assess the multiple-dose pharmacokinetics (PK), safety and tolerability of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [DM]/quinidine sulfate [Q]) in healthy volunteers.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Avanir Pharmaceuticals
Treatments:
Dextromethorphan
Quinidine
Criteria
Inclusion Criteria:

- Healthy adult males

- 18 - 45 years of age

- BMI 18 - 30 kg/m2

Exclusion Criteria:

- History or presence of significant disease

- History of substance abuse and/or alcohol abuse with the past 3 years

- Use of tobacco-containing or nicotine-containing products within 6 months

- Use of any prescription or the over-the-counter medications within 14 days